Dare Bioscience rises as JonesTrading starts coverage with 'buy' rating

Dare Bioscience

01/12/2022 15:06

** Shares of women's health product maker Dare Bioscience
Inc  DARE.O  up 3.4% at 92 cents
    ** Brokerage JonesTrading initiates coverage of DARE with
'buy' rating, citing blockbuster potential in co's contraceptive
device
    ** Brokerage sets PT of $6, sees co as an undervalued player
in the women's health space
    ** If successful, co' s contraceptive device, ovaprene, will
potentially be the only monthly non-hormonal option in the
market - JonesTrading
    ** End-stage study for the device will start in mid-2023,
with top line data in late 2024 or early 2025, says brokerage
    ** JonesTrading expects first commercial U.S. sales in 1H 23
for co' s first FDA approved product, Xaciato, for which DARE
will receive tiered-double digit royalties
    ** All four brokerages covering DARE rate the stock "buy";
their median PT is $5
    ** Including session gains, stock down ~54% YTD
 (Reporting by Sriparna Roy)
 ((Sriparna.Roy@thomsonreuters.com;))